Impact of anti-PCSK9 antibody Alirocumab on lipid-lowering on patient motivation to treatment for hypercholesterolemia.
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Alirocumab (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Therapeutic Use
- 16 Oct 2017 Status changed from not yet recruiting to recruiting.
- 06 Oct 2017 New trial record